A new challenge for Europe: introducing a pediatric quadrivalent vaccine for measles, mumps, rubella, and varicella

International Journal of Infectious Diseases

Volumn 11, Issue SUPPL. 2, 2007, Pages

  Ramet, José ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Measles mumps rubella varicella; MMRV; Quadrivalent vaccine; Varicella

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; CHICKENPOX VACCINE;

CENTRAL NERVOUS SYSTEM DISEASE; CHICKENPOX; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMIC ASPECT; ELECTROLYTE DISTURBANCE; EUROPE; FEVER; HEALTH PROGRAM; HUMAN; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MEASLES; MORBIDITY; MORTALITY; MUMPS; PATIENT COMPLIANCE; PNEUMONIA; RASH; REVIEW; RUBELLA; SKIN INFECTION; UNIVERSAL VACCINATION PROGRAM; VACCINATION;

CHICKENPOX; CHICKENPOX VACCINE; EUROPE; HERPESVIRUS 3, HUMAN; HUMANS; INFANT; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS; RUBELLA; VACCINATION; VACCINES, COMBINED;

EID: 37349000273     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(07)60022-8     Document Type: Review

References (49)

1. CDC. Varicella-related deaths - United States, January 2003- June 2004. MMWR 54 (2005) 272-274. (http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5411a2.htm)
2. Rivest P., Bedard L., Valiquette L., Mills E., Lebel M., Lavoie G., and Crsley J. Severe complications associated with varicella: Province of Quebec, April 1994 to March 1996. Can J Infect Dis 12 (2001) 21-26
3. NAIC. National Advisory Committee on Immunization (NAIC).Update on varicella. Canada Communicable Dis Rep 2004.
4. Rentier B., Gershon A., and The Members of the European Working Group on Varicella (EuroVar). Consensus: Varicella vaccination of healthy children. A challenge for Europe. Pediatric Infect Dis J 23 (2004) 379-389
5. Galil K., Brown C., Lin F., and Seward J. Hospitalizations for varicella in the United States, 1988 to 1999. Pediatric Infect Dis J 21 (2002) 931-934
6. Meyer P., Seward J., Jumaan A., and Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis 182 (2000) 383-390
7. Fairley C., and Miller E. Varicella-zoster virus epidemiology: a changing scene?. J Infect Dis 174 suppl 3 (1996) S314-S319
8. CDC. Recommended childhood and adolescent immunization schedule: United States, July-December 2004. MMWR 53 (2004) Q1-Q3
9. Vazquez M., LaRussa P., Gershon A., et al. Effectiveness over time of varicella vaccine. JAMA 291 (2004) 851-855
10. Nguyen H., Jumaan A., and Seward J. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 352 (2005) 450-458
11. Seward J., Watson B., Peterson C., Mascola L., Pelosi J., Zhang J., et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 287 (2002) 606-611
12. Coudeville L., Paree F., Lebrun T., and Sailly J.-C. The value of vari- cella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 17 (1999) 142-151
13. Banz K., Wagenpfeil S., Neiss A., Hammerschmidt T., and Wutzler P. The cost-effectiveness of routine childhood varicella vaccina- tion in Germay. Vaccine 7 (2003) 11-12
14. CDC. National, state, and urban vaccination coverage among children aged 19-35 months: United Sates, 2003. MMWR Morb Mort Wkly Rep 53 (2004) 658-661
15. Davis M., Patel M., and Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults af- ter introduction of varicella vaccine in the United States. Pediatrics 114 (2004) 786-792
16. Reisinger K., Brown M., Xu J., Sullivan B., Marshall G., Nauert B., et al. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Pediatrics 117 (2006) 265-272
17. Shinefield H., Black S., Thear M., Coury D., Reisinger K., Rothstein E., et al. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Pediatric Infect Dis J 25 (2006) 287-292
18. Grose C. Variation on a theme by Fenner: the pathogenesis of chickenpox. Pediatrics 736 (1981) 735-737
19. Whitley R. Varicella zoster virus infections. In: Isselbacher K., et al. (Ed). Harrison's Principles of Internal Medicine (1998), McGraw-Hill, New York 787-790
20. Deguen S., Chau N., and Flahault A. Epidemiology of chickenpox in France (1991-1995). J Epidemiol Community Health 52 suppl. 1 (1998) 46S-49S
21. Böelle P., and Hanslik T. Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect 129 (2006) 599-606
22. Gabutti G., Penna C., Rossi M., Salmaso S., Rota M., Bella A., et al. Serological Study Group. The seroepidemiology of varicella in Italy. Epidemiol Infect 126 (2001) 433-440
23. Wagenpfeil S., Neiss A., Banz K., and Wutzler P. Empirical data on the varicella situation in Germany for vaccination decisions. Clin Microbiol Infect 10 (2004) 425-430
24. Verschreibungsindex für Pharmazeutika (VIP). Requests: IMS HEALTH GmbH OHG, Hahnstr 2000. 30-2, 60528 Frankfurt am Main, [http://www.imshealth.de].
25. Gil A., San-Martin M., Carrasco P., and andGonzÁlez A. Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine 22 (2004) 3947-3951
26. Salleras L., Dominguez A., Vidal J., Plans P., Salleras M., and Taberner J. Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. Vaccine 19 (2000) 183-188
27. Rawson H., Crampin A., and Noah N. Deaths from chickenpox in England and Wales 1995-7: analysis of routine mortality data. BMJ 323 (2001) 1091-1093
28. Chant K., Sullivan E., Burgess M., Ferson M., Forrest J., Baird L., et al. Varicella-zoster virus infection in Australia (erratum appears in Aust N Z J Public Health 1998 Aug;22(5):630). Aust NZ J Public Health 22 (1998) 413-418
29. In: Atkinson W., Harrison S., Wolfe C., and Nelson R. (Eds). Varicella. Epidemiology and prevention of vaccine-preventable diseases. 7th ed. (2002), Centers for Disease Control and Prevention, U.S. Departmentof Health and Human Services, Atlanta, GA
30. Marshall H., Ryan P., and Roberton D. Uptake of varicella vaccine - a cross sectional survey of parental attitudes to nationally recommended but unfunded varicella immunisation. Vaccine 23 (2005) 5389-5397
31. Preblud S., Orenstein W., and Bart K. Varicella: clinical manifestations, epidemiology and health impact in children. Pediatric Infect Dis J 3 (1984) 505-509
32. Pollard A., Isaacs A., Hermione Lyall E., Curtis N., Lee K., Walters S., et al. Potentially lethal bacterial infection associated with varicella zoster virus. BMJ 313 (1996) 283-285
33. CDC. Prevention of varicella: recommendations of the Advisory committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 45 (1996) 1-25
34. Enders G., Miller E., Cradock-Watson J., Bolley I., and Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 18 (1994) 1548-1551
35. Nolan J., and Sinclair R. Review of managment of purpura fulminans and two case reports. Br J Anaesth 86 (2001) 581-586
36. Halloran M., Cochi S., Lieu T., Wharton M., and Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 140 (1994) 81-104
37. Diez-Domingo J., Aristegui J., Calbo F., Gonzalez-Hachero J., Moraga F., Pena Guitian J., et al. Epidemiology and economic impact of varicella in immunocompetent children in Spain. A nation-wide study. Vaccine 21 (2003) 3236-3239
38. Scuffham P., Lowin A., and Burgess M. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 18 (2000) 407-415
39. Brisson M., and Edmunds W. The cost-effectiveness of varicella vaccination in Canada. Vaccine 20 (2002) 1113-1125
40. Aisha Jumaan. Varicella Vaccination Program in the United States. Presented at the CESP, European Academy of Pediatrics Symposium on Varicella Vaccination, December 2003, Brussels, Belgium.
41. Luman E., Ching P., Jumaan A., and Seward J. Uptake of varicella vaccination among young children in the United States: a success story in eliminating racial and ethnic disparities. Pediatrics 117 (2006) 999-1008
42. Allaert F. Understanding physicians' and parents' attitudes towards varicella vaccination: The OVALE. 24th European Society For Infectious Diseases, Basel, Switzerland, May, 2006. 2006.
43. Watson B. Varicella: a vaccine preventable disease?. J Infect 44 (2002) 220-225
44. White C., Stinson D., Staehle B., Cho I., Matthews H., Ngai A., et al. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group. Clin Infect Dis 24 (1997) 925-931
45. Lieberman J., Williams W., Miller J., Black S., Shinefield H., Henderson F., et al. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatric Infect Dis J 25 (2006) 615-622
46. Shinefield H., Black S., Digilio L., Reisinger K., Blatter M., Gress J., et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatric Infect Dis J 24 (2006) 665-669
47. Watson B. Varicella-zoster vaccine in the USA: success for control of disease severity, but what next?. Expert Rev Anti Infect Ther 3 (2005) 105-115
48. Advisory Committee for Immunization Practices. Recommended Childhood and Adolescent Immunization Sched- ule United States, 2006. http://www.cdc.gov/nip/recs/child-schedule-bw-print.pdf Accessed 23 August 2006.
49. Kuter B., Matthews H., Shinefield H., Black S., Dennehy P., Watson B., Reisinger K., et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatric Infect Dis J 23 (2004) 132-137